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Summary Early diagnosis of invasive pulmonary aspergillosis (IPA) remains difficult due to the
variable performance of the tests used. We compared the performance characteristics
of Aspergillus lateral flow device (LFD) in bronchoalveolar lavage (BAL) vs. BAL-ga-
lactomannan (GM), for the diagnosis of IPA. 311 BAL specimens were prospectively
collected from patients who underwent bronchoscopy from January to May 2013.
Patients at risk for IPA were divided into haematological malignancy (HEM) and
non-HEM groups: solid organ transplants (SOT) (lung transplant (LT) and non-LT
SOT); chronic steroid use (CSU); solid tumour (STU) and others. We identified 96
patients at risk for IPA; 89 patients (93%) were in the non-HEM groups: SOT 57
(LT, 46, non-LT SOT, 11); CSU 21; STU 6, other 5. Only three patients met criteria
for IA (two probable; one possible). Overall sensitivity (SS) was 66% for both and
specificity (SP) was 94% vs. 52% for LFD and GM respectively. LFD and GM perfor-
mance was similar in the HEM group (SS 100% for both and SP 83% vs. 100%
respectively). LFD performance was better than GM among non-HEM SOT patients
(P = 0.02). Most false-positive GM results occurred in the SOT group (50.8%), espe-
cially among LT patients (56.5%). LFD performance was superior with an overall SP
of 95.6% in SOT (P < 0.002) and 97% in LT patients (P = 0.0008). LFD is a rapid
and simple test that can be performed on BAL to rule out IPA.
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Introduction
Invasive pulmonary aspergillosis (IPA) is an important
cause of morbidity and mortality among immunocom-
promised patients.1 Overall, IPA predominates among
patients with acute leukaemia and haematopoietic
stem cell transplant recipients.2 Among solid organ
transplant (SOT) recipients, the highest rates occur in
lung transplant (LT) recipients.3 Early diagnosis and
prompt initiation of antifungal therapy improves
survival of patients with invasive aspergillosis (IA).4,5
The diagnosis of IPA remains challenging given the
lack of a single gold standard test. Current diagnosis of
IPA is based on host factors and clinical, radiological
and microbiological criteria which are neither sensitive
nor specific.6 For instance, a definitive diagnosis of
IPA requires isolating the organism from a normally
sterile site and/or evidence of tissue invasion on histo-
pathology. Obtaining these clinical specimens require
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invasive procedures that are often contraindicated in
patients at risk for IPA due to bleeding diathesis or
other comorbidities.
New strategies for diagnosis and management of
IPA include the use of non-invasive biomarkers (i.e.
galactomannan (GM) and 1,3 beta-d-glucan). The role
of serum and bronchoalveolar lavage (BAL) GM for
the diagnosis of IPA has been best established in
patients with haematological malignancies.7 Con-
versely, the role of these biomarkers in other patients
at risk for IPA such as SOT recipients has not been
established mainly because of the significant variation
in performance observed in these patients.8 In addi-
tion, factors such as cost and outsourcing to reference
laboratories limits testing frequency and timely result
availability.
Aspergillus immuno-chromatographic lateral flow
device (LFD) is a novel technique that uses an Aspergil-
lus – specific monoclonal antibody (mAb JF5).9 Asper-
gillus LFD enables the point-of-care testing using the
same technology used for the rapid diagnosis of preg-
nancy.9,10 Indeed, recent studies report sensitivity,
specificity, positive and negative predictive values up
to 100%, 95%, 80% and 100%, respectively, for the
diagnosis of IPA.11–13
We sought to determine the performance character-
istics of the LFD using BAL for the diagnosis of IPA in
patients at risk of invasive fungal infection (IFI) who
underwent bronchoscopy at the Henry Ford Health
System. Second, we compared the performance of
BAL-LFD to that of BAL-GM.
Material and methods
We prospectively collected aliquots of all BAL speci-
mens obtained from bronchoscopies performed at
HFHS from January 2013 to May 2013. These BAL
aliquots were stored at 20 °C for GM and LFD test-
ing. All BAL specimens were stored at room tempera-
ture for up to 2 h or at 4 °C for up to 24 h before
being stored at 20 °C. Specimens remained frozen up
to 6 months before GM and LFD testing was per-
formed. Clinical information regarding risk factors and
diagnostic criteria for IPA was collected by retrospec-
tive chart review. Patients were classified as risk for
IPA according to the current European Organization
for Research and Treatment of Cancer /Mycoses Study
Group (EORTC/MSG) guidelines for IFI.6 For this study,
we extended the revised EORCT/MSG host criteria to
include a heterogeneous group of otherwise immuno-
suppressed patients at risk of contracting IPA (i.e. criti-
cally ill patients, severe burns and HIV patients with
CD4 ≤ 200 cells/mm3).14 Isolation of Aspergillus in
culture was utilised as mycological criteria for the
diagnosis of IPA. Serum and BAL Aspergillus GM were
not used as mycological criterion for the study. Only
patients at risk for IPA were included in the study and
were subsequently classified based on their underlying
risk factor for IFI into haematological malignancy
(HEM) group and non-HEM group. The non-HEM
group included SOT recipients (who were further sub-
divided into LT group and non-LT SOT group), chronic
steroid use, solid tumour and others.
Retrospective Aspergillus GM (PlateliaTM Aspergillus
EIA) testing of BAL fluid (BAL-GM) from patients at
risk for IPA was performed at Mira Vista Diagnostics
(Indianapolis, IN, USA) according to manufacturers’
procedure. An optical density (OD) index ≥0.5 was
considered positive.
The Aspergillus-LFD was performed on stored BAL
fluid from all patients included in the study. The BAL-
LFD testing was performed in the Infectious Disease
Research Laboratory at HFHS, following the manufac-
turer’s method process (Isca Diagnostics, Truro, Corn-
wall, UK). Results of BAL-LFD testing were read at
10 min after applying the fluid to the LFD sample
well.15 Qualitative results were interpreted as a posi-
tive [both the test (T) and the control (C) line were
present] or negative [only red line appeared in the
control (C) zone] (Fig. 1).
We compared the diagnostic performance of LFD
and GM in BAL fluid from patients at risk for IPA. The
BAL-LFD results were blindly analysed by one of the
investigators in this study.
Fisher’s exact test was used to test the null hypothe-
sis that GM and LFD have the same specificity.
(a)
(b)
Figure 1 Aspergillus lateral flow device (LFD) qualitative results
were interpreted as a ‘positive’ if both the test (T) and the control
(C) line were present or ‘negative’ if only red line appeared in
the control (C) zone. (a) Positive LFD test result. (b) Negative
LFD test.
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Results
We prospectively collected BAL samples from 311
patients. Of these, 96 patients were identified at risk
for IPA. The enrolment and distribution of patients is
summarised in Fig. 2. Mean patient age was 61 years
(range: 35–81), 59 were female. Most patients, 89 of
96 (93%) were in the non-HEM groups: 57 SOT
patients (LT: 46 patients, non-LT SOT: 11 patients),
chronic steroid use: 21 patients, solid tumour: six
patients and other: five patients. Only three patients in
the study met criteria for IPA (2 probable; 1 possible
IPA). The two patients with probable IPA had compat-
ible clinical and radiographical findings and a positive
BAL culture with Aspergillus species. One of these two
cases was a haematological cancer patient with posi-
tive BAL-LFD and positive serum and BAL-GM (OD
index 0.86 and 7.7 respectively). The patient was
started on treatment with voriconazole but died 6 days
later. The other patient had HIV infection with a CD4
cell count of 110/mm3. The patient was treated with
voriconazole. Serum and BAL-GM were negative. Sub-
sequent workup revealed Pseudomonas aeruginosa pneu-
monia and oesophageal squamous cell carcinoma with
metastasis to the lungs. Given the alternative diagnosis
and the development of QTc segment prolongation,
voriconazole was stopped after 2 weeks. The patient
was alive at 30 day follow-up. Retrospective BAL-LFD
testing was negative. Lastly, one critically ill patient
in the surgical intensive care unit met criteria for
possible IPA. Fungal culture of BAL fluid was not
performed. Clinically, the suspicion for IPA was low
and the patient was not treated with antifungals.
This patient died within 2 weeks of admission.
Reported cause of the death was multifactorial (stage
IV congestive heart failure secondary to ischaemic
cardiomyopathy complicated by refractory cardiogenic
and septic shock, multiorgan failure). Serum GM
result received postmortem was positive (OD index
2.67). Retrospective BAL-LFD and BAL-GM testing for
this research study were positive (GM OD index was
4.02).
The overall sensitivity and specificity of BAL-GM for
IPA was 66% and 52% respectively. Sensitivity and
specificity of BAL-LFD were 66% and 94% respectively.
Test performance was similar for BAL-LFD and BAL-GM
in the HEM group (sensitivity 100% for both and speci-
ficity 83% vs. 100% respectively). However, BAL-LFD
showed a better performance than BAL-GM in the non-
HEM groups, particularly in the SOT group (P = 0.002)
(Table 1). Forty-four of 96 (45%) BAL-GM showed
false-positive results, using a BAL-GM cut-off ≥0.5 OD
index. False-positive BAL-GM were more frequent in the
SOT group (29/57 patients; 50.8%), especially among
LT recipients (26/46 patients; 56.5%). False-positive
BAL-GM results were associated with lower OD index
values (average: 1.49; range: 0.5–7.18) compared to
true positive results (average: 5.86; range 4.02–7.7).
Increasing the BAL-GM cut-off to ≥1.0 OD index
improved the specificity compared to BAL-GM cut-off at
Figure 2 Patients Breakdown. BAL: bronchoalveolar; IA: inva-
sive aspergillosis; N: number of patients.
Table 1 Specificity of Aspergillus lateral flow device test and






ODI) LFD P value
GM
(≥1.0
ODI) LFD P value
HEM group
(n = 7)






0.49 0.96 <0.000001 0.75 0.96 <0.0021
Lung TX
(n = 46)
0.43 0.97 <0.0001 0.71 0.97 0.0008
Non-lung
(n = 11)
0.72 0.90 0.59 0.90 0.90 1.0
Solid tumour
(n = 6)
0.16 1.00 0.02 0.66 1.00 0.45
Chronic
steroid
use (n = 21)
0.71 0.90 0.24 0.76 0.90 0.40
Other (n = 5) 0.30 1.00 0.4 0.33 1.00 0.4
GM, galactomannan; LFD, lateral flow device; ODI, optic density
index; HEM group, haematological malignancy and peripheral
stem cell transplant group; SOT group, solid organ transplant
recipients, further divided into lung transplant (lung Tx) group
and non-lung groups).
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≥0.5 OD index (74% vs. 52%). Conversely, BAL-LFD
performance was superior with an overall specificity of
95.6%, particularly among SOT and LT recipients
(P < 0.002 and 0.0008 respectively).
Seven patients had positive BAL-LFD test results.
Two of them met criteria of IPA (true positive results)
and were described above. False-positive BAL-LFD
results were observed in five patients from the non-
Hem group (SOT group, two; chronic steroid use, two;
solid tumour, one). Four of these five patients also
tested falsely positive for BAL-GM. The BAL fluid fun-
gal cultures from all five patients were negative.
Results are summarised in Table 2.
Eight patients grew mould from fungal cultures of
BAL fluid (Aspergillus species four, other moulds: four).
Among the four patients with Aspergillus species in
BAL fungal culture, only two patients met criteria of
probable IPA by EORTC/MSG definition. These two
patients were described above. One of them tested posi-
tive for BAL-LFD (true positive) and BAL-GM (7.7 OD
index) (true positive), whereas the other patient tested
negative for BAL-LFD and GM (false negative). The
remaining two patients with Aspergillus species in BAL
fungal culture did not meet criteria for IPA. Both
patients had a positive BAL-GM at 0.83 and 1.35 OD
index, respectively (false positive), and both had nega-
tive BAL-LFD (true negative).
We also evaluated cross-reactivity of BAL-GM and
BAL-LFD with other moulds growing from BAL cul-
tures of 4 LT recipients. Fungal BAL cultures in these
patients yielded Fusarium sp, Exophiala jenselmei, Em-
monsia sp, and Penicillium sp respectively. None of
these patients met EORCT/MSG definition criteria for
IPA and isolated moulds were regarded as contami-
nant. The results of BAL-LFD were negative in all four
patients (true negative), whereas BAL-GM results were
positive in two of these four patients (false positive).
Cross-reaction of BAL-GM was observed with Fusarium
sp and Emmonsia sp.
Discussion
We evaluated the diagnostic performance of the novel
Aspergillus LFD and GM done on BAL obtained from a
large and heterogeneous group of patients at high risk
for IPA. In our study, the overall performance of BAL-
LFD for the diagnosis of IPA was superior to BAL-GM,
particularly among patients in the non-Hem group.
Indeed, specificity of BAL-LFD was higher in the SOT
group, especially among LT patients. These findings
confirm those of Willinger et al.13, that performance of
BAL-LFD from 47 SOT patients demonstrated very
high specificity and a NPV greater than 97% for diag-
nosis of IPA. Similarly, a smaller study reported on the
performance of 10 SOT patients, with emphasis on the
accuracy of the BAL-LFD to diagnose IPA and the abil-
ity of the test to exclude the diagnosis of IPA in this
patient population.11
Classic diagnostic criteria for the diagnosis of IPA
are difficult to apply in the SOT patients.3 For
instance, the halo sign on computed tomography (CT)
scan of the lungs is rarely observed in SOT recipients.
Most SOT patients with IPA will present with focal
consolidation or infiltrates and nodular lesions in CT
of the chest.16 The clinical utility of culture methods is
also limited. Airway colonisation with Aspergillus sp
within 6 months after lung transplantation could be
as high as 46% despite prolonged anti-mould prophy-
laxis.16,17 Similarly, diagnostic performance of non-
culture diagnostic assays such as BAL-GM is variable
in this patient population. A recent meta-analysis
study conducted to determine the role of BAL-GM for
the diagnosis IPA showed that test sensitivity and
specificity varied (up to 84% and 95% respectively)
depending on the population tested and the cut-off
point value used.8 The GM assay has been approved
by the Food and Drug Administration (FDA) for serum
and BAL.18,19 In the United States, serum or BAL- GM
value ≥ 0.5 OD index is considered positive. Using this
Table 2 Summary of seven patients with positive bronchoalveolar lateral flow device test results.
Risk factor IPA BAL-LFD result BAL-GM result BAL culture result
SOT (non-lung) No-IPA False positive False positive (7.18 ODI) No growth
Chronic steroid use No-IPA False positive False positive (1.67 ODI) No growth
Chronic steroid use No IPA False positive False positive (5.0 ODI) No growth
HEM group Probable IPA True positive True positive (7.7 ODI) Aspergillus fumigatus
Solid tumour No IPA False positive False positive (0.94 ODI) No growth
SOT (lung transplant) No IPA False Positive True negative (0.27 ODI) No growth
Other (critically ill patient) Possible IPA True Positive True positive (4.02 ODI) Not available
BAL, bronchoalveolar lavage; GM, galactomannan; HEM group, haematological malignancy and peripheral stem cell transplant group;
IPA, invasive pulmonary aspergillosis; LFD, lateral flow device; ODI, optic density index; SOT group, solid organ transplant recipients,
further divided into lung transplant non-lung groups).
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suggested cut-off point, the reported sensitivity and
specificity of the serum GM assay was 80.7% and
89.2% respectively.20 However, the threshold for posi-
tive BAL-GM remains under debate due to its great
impact on test performance. In our study, increasing
the BAL-GM cut-off to ≥1.0 OD index improved test
specificity from 52% to 74%. This is in accordance
with prior reports showing that increasing the cut-off
value to ≥1.0 OD index improved sensitivity and speci-
ficity of the test (up to 60% and 98% respectively).21
False-positive BAL-GM test results in SOT particu-
larly among LT recipients are not uncommon.3,8 Our
study showed a high rate of false-positive results
using BAL-GM in SOT patients (50.8%), particularly
among LT recipients (56%). Only two of 44 false-posi-
tive BAL-GM results were due to cross-reactivity with
other moulds. Cross-reactivity of GM with other fun-
gal antigens has been reported.22,23 In our study,
BAL-GM cross-reacted with Fusarium sp and Emmon-
sia sp. The cause of false-positive BAL-GM results in
the remaining 42 patients could not be determined.
These findings are consistent with prior reports on
the high incidence of false-positive BAL-GM testing in
SOT patients (50%), particularly among LT recipients
(up to 56%) likely due to frequent Aspergillus coloni-
sation in these patients.24 On the basis of these data,
we recommend BAL-GM should be used as an adjunc-
tive tool for the diagnosis of IPA and test results
should be interpreted with caution in this patient pop-
ulation. It is critical that non-invasive biomarkers for
the diagnosis of IPA are used in the right clinical
context.
In our study, no cross-reactivity was observed with
BAL-LFD. Five BAL-LFD results were falsely positive,
but the cause for false-positive results could not be
determined. False-positive test results and potential
cross-reactivity of BAL-LFD with other fungal antigens
have been described. Initial in vitro studies showed
that the MAb JF5 used in the LFD cross-reacted with
antigens from Paecilomyces variotti and non-pathogenic
Penicillium species.9,11,13 In a study of 47 BAL samples
from SOT recipients, Willinger et al.13 reported six
false-positive BAL-LFD results. Four of these patients
had positive BAL culture. One patient had possible
invasive infection caused by Penicillium sp, the remain-
ing three patients had Aspergillus species growing in
BAL culture, but none of them met criteria for IPA.
Similarly, Hoenigl et al.11 reported cross-reactivity
with Penicillium species in 1 of 37 clinical BAL
samples.
One study reports on a patient (1 of 47) with false-
negative BAL-LFD in a patient with diagnosis of
probable IPA in a kidney transplant recipient, with a
BAL-GM of 24.9 OD index and negative BAL cul-
ture.13 In another studies, no false-negative results
were observed, even among patients receiving antifun-
gal prophylaxis.11 We were unable to fully evaluate
the occurrence of false-negative results of either BAL-
GM or BAL-LFD because of our study design. However,
we observed one BAL-LFD false-negative result in an
HIV patient with probable IPA who also tested nega-
tive for BAL-GM. Interestingly, an alternative diagnosis
(i.e. Pseudomonas aeruginosa pneumonia and oesopha-
geal squamous cell carcinoma with metastasis to the
lungs) was found to explain this patient’s symptoms
and antifungals were stopped within 2 weeks. Diver-
gent results in this patient may be explained by the
fact that he did not have probable IPA in the first
place and it could be inferred that BAL-LFD and GM
test results were indeed accurate.
Our findings suggest that Aspergillus LFD in BAL
fluid may be considered as a valuable aid to rule out
IPA in high-risk population, especially in LT recipients
that have a high prevalence of airway colonisation
with Aspergillus species. Indeed, having a rapid and
accurate test to help rule out the presence of IPA in
these patients would be important to prevent over-
treatment with broad-spectrum antifungal agents and
the potential drug–drug interactions and toxicities
associated with these agents. The four studies evaluat-
ing the performance of BAL-LFD for the diagnosis of
IPA vs. no-IPA are summarised in Table 3.
Our study has limitations that should be acknowl-
edged, including the small sample size, with only three
cases of probable/possible IPA. Another important lim-
itation is that classic EORTC/MSG definition criteria
for the diagnosis of IA are difficult to apply in non-
neutropenic patients, particularly SOT recipients which
represent the largest group in our study. Furthermore,
we used very inclusive eligibility criteria, we have
included all patients at risk for IPA who underwent
bronchoscopy and had BAL fluid obtained regardless
the indication for this procedure (e.g.: surveillance
bronchoscopy following LT, mucus plug removal, sus-
pected pneumonia, aspiration, etc.). This means that
most of our patients did not undergo bronchoscopy for
suspected IPA. Thus, it is not surprising that only
three patients in our cohort met criteria of possible/
probable IPA. Consequently, our statistical analysis
was limited to specificity. More patients with probable/
proven IPA (true positive) should be included in future
studies to evaluate sensitivity of the test. Only after
evaluating both sensitivity and specificity would we
will be able to make a more definitive comparison of
© 2015 Blackwell Verlag GmbH
Mycoses, 2015, 58, 368–374372
M. H. Miceli et al.
the diagnostic performance of both methods (BAL-LFD
vs. BAL-GM).
Finally, retrospective BAL-GM testing should be
mentioned as a potential limitation of this study. How-
ever, a recent study comparing prospective real-time
vs. retrospective BAL-GM testing showed minimal
change in the BAL-GM OD index when BAL specimens
were stored at 20 °C for up to 11 months.25
In summary, our data demonstrate that BAL-LFD is
a promising tool for the diagnosis of IPA. Aspergillus
LFD is a rapid, simple, potential point-of-care and
inexpensive test performed on BAL that could help to
Table 3 Summary of studies on the performance of lateral flow device testing in bronchoalveolar fluid of patients at risk of invasive
pulmonary aspergillosis.
References Objective Study patients
Test performance for the
diagnosis of IPA vs. no-IPA Comments
Hoenigl
et al. [11]
Evaluation of BAL-LFD vs.
BAL-GM (cut-off ≥1.0
ODI) and





of IPA [HM, 27;




Indication for BAL testing:
clinical suspicion of IPA
BAL-LFD: SS 100%; SP 81%;
PPV 71%; NPV 100%
Cross-reaction: Penicillium sp (1)
False-negative BAL-LFD results: none
False-negative BAL-GM results:
five (all five patients met criteria of
possible IPA, had positive BAL-LFD
and were on anti-mould prophylaxis)














67 BAL from patients at risk
for IPA (HM, 43;
SOT, 4; CLD,
12; ICU, 4; AIDS, 2;
other, 2)
IPA 26 patients: proven (3),
probable (7), possible (16)
Indication for BAL testing:
clinical suspicion of IPA
51 of 67 had all 5 test results available
BAL-GM ODI ≥0.5: SS 80%; SP 98%;
PPV 89%; NPV 95%
BAL-GM ODI ≥1.0: SS 70%; SP 98%;
PPV 88%; NPV 93%;
BAL fungal culture: SS 50%; SP 95%;
PPV 71%; NPV 89%
BAL-BDG: SS 80%; SP 76%; PPV 44%;
NPV 94%
BAL Aspergillus PCR: SS 70%; SP 100%;
PPV 100%; NPV 93%
BAL-LFD: SS 80%; SP 95%; PPV 80%;
NPV 95%










Evaluation of BAL-LFD vs.
BAL-GM





47 BAL from SOT
patients (LT, 26).
IPA 22 patients: probable or
proven (11) and
possible (11)
Indication for BAL testing:
clinical suspicion of IPA
BAL-LFD: SS 91%; SP 83%; PPV 63%;
NPV 97%
False-positive results (6/25):
Cross-reactivity with Penicillium sp (1),
LT patient with Aspergillus sp cultured
from BAL (3), unknown (2)
False-negative results (1/22)
BAL-GM and fungal
culture were used as
mycological criterion for
the diagnosis of IPA.






and ≥1.0) vs. BAL-LFD
the diagnosis
of proven, probable, or
possible IPA
in patients at risk.
96 BAL from patients
at risk of
IPA {HM, 7; non-HM,
89 [SOT 57,
(LT: 46; non-LT
SOT: 11), CSU 21,
STU 6, other 5]}
IPA 3 patients





BAL-LFD: SS 66%; SP 94%
BAL-GM ODI >0.5: SS 66%; SP 52%
BAL-GM ODI ≥1.0: SS 66%; SP 74%
False-positive results BAL-LFD: 5;
cross-reaction: none
False-negative results BAL-LFD: 1




not used as mycological
criterion for the
diagnosis of IPA.
Analysis was limited due
to small number of
patients with IPA
AIDS, acquired immune deficiency syndrome; BAL, bronchoalveolar lavage; BDG, beta-D-glucan; CLD, chronic lung disease; CSU,
chronic steroid use; GM, galactomannan; HM, haematological malignancy and peripheral stem cell transplant recipients; ICU, intensive
care unit patients; IPA, invasive pulmonary aspergillosis; LFD, lateral flow device; LT, lung transplant recipients; NPV, negative predic-
tive value; ODI, optic density index; PPV, positive predictive value; SOT, solid organ transplant recipients; SP, specificity; SS, sensitivity;
STU, solid tumour.
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rule out IPA in high-risk population, particularly LT
recipients. More studies are needed to further deter-
mine the role of BAL-LFD in patients with suspected
diagnosis of IPA.
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